Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyoshi Kunimoto

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Hematology|April 16, 2023
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndromeHiroyoshi Kunimoto, Ayaka Miura, Ayaka Maeda, et al.
Cancer Cell|December 26, 2017
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor SensitivityHiroyoshi Kunimoto, Cem Meydan, Abbas Nazir, et al.
International Journal of Hematology|February 1, 2025
Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilitiesJunji Ikeda, Norio Shiba, Shota Kato, et al.
Hematology (Amsterdam, Netherlands)|May 27, 2022
Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantationHaruka Teshigawara-Tanabe, Maki Hagihara, Jun Aoki, et al.
Journal of the American Heart Association|November 27, 2024
Clonal Hematopoiesis in Chronic Thromboembolic Pulmonary HypertensionMizuki Momoi, Yoshinori Katsumata, Hiroyoshi Kunimoto, et al.
Scientific Reports|October 23, 2025
BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemiaWeijia Zang, Yui Koike, Koutarou Nishimura, et al.
Haematologica|June 12, 2025
Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemiaJunji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, et al.
Hemasphere|July 14, 2025
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, et al.
Cell Reports|January 6, 2021
OGT Regulates Hematopoietic Stem Cell Maintenance via PINK1-Dependent MitophagyKoichi Murakami, Daisuke Kurotaki, Wataru Kawase, et al.
Cancer Discovery|April 15, 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic ModifiersJacob L Glass, Duane Hassane, Bas J Wouters, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Hematology|April 16, 2023
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndromeHiroyoshi Kunimoto, Ayaka Miura, Ayaka Maeda, et al.
Cancer Cell|December 26, 2017
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor SensitivityHiroyoshi Kunimoto, Cem Meydan, Abbas Nazir, et al.
International Journal of Hematology|February 1, 2025
Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilitiesJunji Ikeda, Norio Shiba, Shota Kato, et al.
Hematology (Amsterdam, Netherlands)|May 27, 2022
Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantationHaruka Teshigawara-Tanabe, Maki Hagihara, Jun Aoki, et al.
Journal of the American Heart Association|November 27, 2024
Clonal Hematopoiesis in Chronic Thromboembolic Pulmonary HypertensionMizuki Momoi, Yoshinori Katsumata, Hiroyoshi Kunimoto, et al.
Scientific Reports|October 23, 2025
BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemiaWeijia Zang, Yui Koike, Koutarou Nishimura, et al.
Haematologica|June 12, 2025
Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemiaJunji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, et al.
Hemasphere|July 14, 2025
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, et al.
Cell Reports|January 6, 2021
OGT Regulates Hematopoietic Stem Cell Maintenance via PINK1-Dependent MitophagyKoichi Murakami, Daisuke Kurotaki, Wataru Kawase, et al.
Cancer Discovery|April 15, 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic ModifiersJacob L Glass, Duane Hassane, Bas J Wouters, et al.
Pageof 4